NETSCOUT Combines Leading Global Threat Intelligence With Machine Learning to Protect Enterprises From Rapidly Spreading Dynamic DDoS Attacks
11.7.2023 13:05:00 EEST | Business Wire | Press release
NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT), a leading provider of performance management, cybersecurity, and DDoS attack protection solutions, today released its latest version of Arbor Edge Defense (AED) which includes new ML-based Adaptive DDoS Protection.
According to NETSCOUT's latest DDoS Threat Intelligence Report, there has been a significant increase in a new breed of dynamic DDoS attacks that use multiple vectors and techniques to launch botnet-based, direct-path, state exhaustion, and application-layer attacks designed to evade conventional static network and cloud-only-based DDoS defense.
Every enterprise is at grave risk today if they don’t deploy an effective DDoS solution on-premises to protect their network edge, internet-facing services, and critical stateful infrastructure such as firewalls and load balancers from these constantly evolving attacks. Attackers can send dynamic direct-path DDoS traffic at any time, and they can quickly change attack vectors during the attack making them nearly impossible to defend without the right technology. With AED’s Adaptive DDoS Protection, IT teams now have a scalable, always-on stateless packet processing solution that uses unmatched visibility into more than 50% of all internet traffic, global, real-time DDoS attack threat intelligence, decades of DDoS mitigation experience, and machine learning (ML) software intelligence to automatically detect, adapt to, and mitigate dynamic DDoS attacks.
“As cyber threats become more sophisticated and dynamic, IT teams need to out-smart bad actors with the ability to adapt and surgically block unwanted traffic at the network edge,” said Scott Iekel-Johnson, AVP, DDoS and Threat Intelligence at NETSCOUT. “With unmatched real-time visibility into global DDoS attack activity and decades of mitigation experience, no one knows more about DDoS attacks than NETSCOUT. With AED’s Adaptive DDoS Protection, enterprises can take advantage of our DDoS attack expertise and minimize unnecessary workloads that force expensive upgrades with an always-on product that can scale to protect every edge from a single pane of glass.”
Automated AED Protects Enterprises from Threats
Deployed at the Internet edge in front of any firewall, AED screens incoming and outgoing traffic using stateless packet processing, global DDoS threat intelligence, and ML to block inbound cyber threats, including DDoS attacks and other bulk malicious traffic. It protects and reduces the load on firewalls, load balancers, or VPN concentrators and stops the proliferation of malware within an organization. AED can also block outbound communications sent from compromised internal devices to sites run by bad actors to prevent data breaches and other malware activity. It contains the threat while giving the IT team time to investigate and remove it before it can cause further damage. In the event of a large volumetric DDoS attack, AED’s cloud signaling feature integrates with cloud DDoS protection providers, including NETSCOUT’s Arbor Cloud, to intelligently and automatically coordinate attack response between cloud-based volumetric protection and on-premise adaptive DDoS attack protection.
Visibility into 50% of All Internet Traffic
NETSCOUT ASERT, the company’s expert security research and DDoS attack mitigation team, works with over 500 Internet Service Providers (ISPs) to maintain a unique sensor network called ATLAS. With over 400 Tbps of international transit traffic received every second of every day from 93 countries, 600 industry verticals, and more than 31,000 autonomous systems, ATLAS provides ASERT with unmatched visibility into more than 50% of all internet traffic and real-time DDoS attack activity. ASERT analyzes the ATLAS data and distributes its findings to the Arbor Edge Defense (AED) solution via the ATLAS Intelligence Feed (AIF). AIF continually arms AED with highly curated intelligence that constantly updates the IP addresses of bots and reflectors/amplifiers actively participating in DDoS attacks around the globe. Created from real-world ASERT mitigation experience, AED’s Adaptive DDoS defense capabilities use ML-based algorithms to automatically recommend changes to attack countermeasures designed to stop dynamic DDoS attacks.
To learn more about how Adaptive DDoS Protection for AED automatically protects networks from dynamic DDoS attacks, visit our website.
About NETSCOUT
NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) protects the connected world from cyberattacks and performance and availability disruptions through the company’s unique visibility platform and solutions powered by its pioneering deep packet inspection at scale technology. NETSCOUT serves the world’s largest enterprises, service providers, and public sector organizations. Learn more at www.netscout.com or follow @NETSCOUT on LinkedIn, Twitter, or Facebook.
©2023 NETSCOUT SYSTEMS, INC. All rights reserved. NETSCOUT, the NETSCOUT logo, Guardians of the Connected World, Visibility Without Borders, Adaptive Service Intelligence, Arbor, ATLAS, Cyber Threat Horizon, InfiniStream, nGenius, nGeniusONE, and Omnis are registered trademarks or trademarks of NETSCOUT SYSTEMS, INC., and/or its subsidiaries and/or affiliates in the USA and/or other countries. Third-party trademarks mentioned are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230711112959/en/
Contact information
Maribel Lopez
Manager, Marketing & Corporate Communications
+1 781 362 4330
maribel.lopez@netscout.com
Chris Shattuck
Finn Partners for NETSCOUT
+1 404 502 6755
NETSCOUT-US@FinnPartners.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
